Matthew Parris

Technik-/Wissenschafts-/F&E-Leiter bei TRAWS PHARMA, INC.

Health Technology

Consumer Services

Aktive Positionen von Matthew Parris

Unternehmen	Position	Beginn	Ende
TRAWS PHARMA, INC.	Technik-/Wissenschafts-/F&E-Leiter	01.08.2018	-

Unternehmen	Position	Beginn	Ende
Eleison Pharmaceuticals, Inc. Eleison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Eleison Pharmaceuticals, Inc. engages in the acquisition, development and commercialization of clinical stage drug candidates for orphan oncology indications. Its portfolio of drug candidates consists of glufosfamide, inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD). The company was founded by Edwin J. Thomas on October 14, 2009 and is headquartered in Princeton, NJ.	Corporate Officer/Principal	-	-
AEGERION PHARMACEUTICALS, INC.	Corporate Officer/Principal	-	-
INOVIO PHARMACEUTICALS, INC.	Corporate Officer/Principal	-	-

Imperial College London

Undergraduate Degree

International

Vereinigte Staaten	5
Vereinigtes Königreich	2

Operativ

Corporate Officer/Principal	3
Chief Tech/Sci/R&D Officer	1
Undergraduate Degree	1

Sektoral

Health Technology	5
Consumer Services	2

Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Börsennotierte Unternehmen	2
TRAWS PHARMA, INC.	Health Technology
INOVIO PHARMACEUTICALS, INC.	Health Technology

Private Unternehmen	2
Eleison Pharmaceuticals, Inc. Eleison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Eleison Pharmaceuticals, Inc. engages in the acquisition, development and commercialization of clinical stage drug candidates for orphan oncology indications. Its portfolio of drug candidates consists of glufosfamide, inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD). The company was founded by Edwin J. Thomas on October 14, 2009 and is headquartered in Princeton, NJ.	Health Technology
Aegerion Pharmaceuticals, Inc. Aegerion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aegerion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development and commercialization of therapies for patients with debilitating rare diseases. The company was founded by David I. Scheer, Gerald L. Wisler and William H. Lewis in 2005 and is headquartered in Cambridge, MA.	Health Technology

Private Unternehmen

Health Technology